| Literature DB >> 29264668 |
Ildikó László1, Gábor Demeter2, Nándor Öveges2, Dániel Érces3, József Kaszaki3, Krisztián Tánczos2, Zsolt Molnár2.
Abstract
BACKGROUND: Fluid resuscitation remains a cornerstone in the management of acute bleeding. According to Starling's "Three-compartment model", four-times more crystalloids have the same volume effect as colloids. However, this volume-replacement ratio remains a controversial issue as it may be affected by the degradation of the endothelial glycocalyx layer, a situation often found in the critically ill. Our aim was to compare colloid and crystalloid based fluid resuscitation during an experimental stroke volume index (SVI) guided hemorrhage and resuscitation animal model.Entities:
Keywords: Colloid; Crystalloid; Glycocalyx; Volume-replacement ratio
Year: 2017 PMID: 29264668 PMCID: PMC5738334 DOI: 10.1186/s40635-017-0165-y
Source DB: PubMed Journal: Intensive Care Med Exp ISSN: 2197-425X
Fig. 1Schematic flowchart illustrating the experimental protocol. After baseline measurements, animals were bled until the stroke volume index (SVI) decreased by 50% (T 0). Then, measurements were repeated and the animals were randomized into the balanced crystalloid (Ringerfundin®, RF B. Braun AG) or colloid (Voluven®, HES) groups. The difference of the SVI T bsl − SVI T 0 was divided into four equal steps (T 1–4) and i.v. fluids were administered to reach these target values
Demographics, blood loss, and fluid therapy
| HES ( | RF ( |
| |
|---|---|---|---|
| Weight (kg) | 26.0 [22.5–28.0] | 25.5 [24.0–37.0] | 0.280 |
| Height (cm) | 118.0 [112.5–120.0] | 115.0 [110.0–125.0] | 0.981 |
| BSA (m2) | 0.91[0.855–0.97] | 0.94 [0.975–1.115] | 0.401 |
| Shed blood (mL) | 505.6 ± 159.3 | 469.7 ± 127.3 | 0.529 |
| Total blood loss (mL/m2) | 552.8 ± 174.9 | 481.1 ± 95.2 | 0.197 |
| PiCCO measurements ( | 23 ± 8 | 25 ± 5 | 0.422 |
| Saline used for PiCCO measurements (mL) | 230.0 ± 81.5 | 252.1 ± 58.2 | 0.422 |
| Urine (mL) | 450[350–626]# | 759.5[421–1110] | < 0.001 |
Data are presented as mean ± standard deviation or median [IQR]
# p < 0.05 significantly different between groups
Hemodynamic parameters during hemorrhage and fluid resuscitation
| Group |
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| Stroke volume index (mL/m2) | HES | 34.4 ± 7.5† | 16.5 ± 3.6* | 22 ± 4.7*† | 25.8 ± 5.2*† | 30.3 ± 5.7*† | 34.3 ± 7.2† |
| RF | 33 ± 3.6† | 15.4 ± 2.2* | 19.6 ± 3.8*† | 23.9 ± 4.0*† | 28.0 ± 5.5*† | 32.3 ± 3.3† | |
| Cardiac index (L/min/m2) | HES | 3.25 ± 0.23† | 1.58 ± 0.27* | 2.38 ± 0.27*† | 2.75 ± 0.29*† | 3.36 ± 0.34#† | 3.99 ± 0.54#† |
| RF | 3.14 ± 0.19† | 1.84 ± 0.4* | 2.22 ± 0.43*† | 2.52 ± 0.34*† | 2.90 ± 0.29*† | 3.39 ± 0.36† | |
| Mean arterial pressure (mmHg) | HES | 122 ± 15.2† | 82 ± 25.9* | 110 ± 27.5#† | 114 ± 24.5#† | 121 ± 25.2#† | 123 ± 23.7#† |
| RF | 124 ± 16.6† | 69 ± 17.1* | 77 ± 18.3*† | 90 ± 15.4*† | 99 ± 18.0*† | 101 ± 9.9*† | |
| Heart rate (beats/min) | HES | 95 ± 18.5 | 105 ± 27.5 | 106 ± 24.3* | 106 ± 24.2* | 109 ± 20.8* | 117 ± 16.7#*† |
| RF | 97 ± 18.4† | 111 ± 19.6* | 107 ± 16.2*† | 106 ± 18.7*† | 102 ± 15.1† | 102 ± 13.8† | |
| Global end-diastolic volume (mL/m2) | HES | 361 ± 60.6† | 222 ± 36.4* | 267 ± 45.2*† | 283 ± 46.2*† | 333 ± 54.2# † | 351 ± 55.5# † |
| RF | 329 ± 46.8† | 212 ± 52.5* | 231 ± 51.6*† | 249 ± 40.8*† | 280 ± 47.3*† | 300 ± 42.9*† | |
| Stroke volume variation (%) | HES | 11.4 ± 5.9† | 23 ± 7.0* | 18.1 ± 6.8*† | 13.8 ± 3.2† | 11.7 ± 4.7† | 6.7 ± 2.7#*† |
| RF | 11.7 ± 3.0† | 21.8 ± 6.0* | 19.3 ± 5.4* | 16.3 ± 4.4*† | 13.8 ± 4.4† | 10.3 ± 2.5† | |
| Pulse pressure variation (%) | HES | 10.3 ± 3.0† | 24.2 ± 6.0* | 16.6 ± 3.7#*† | 13.1 ± 3.5† | 9.8 ± 2.0† | 6.9 ± 2.3† |
| RF | 10.5 ± 4.8† | 24.4 ± 5.4* | 22.1 ± 6.2* | 16.8 ± 5.7*† | 13.8 ± 5.6*† | 10.3 ± 2.4† | |
| Systemic vascular resistance index | HES | 2937 ± 359 | 3517 ± 1094 | 3618 ± 831#* | 3183 ± 650 | 2796 ± 483† | 2309 ± 277*† |
| RF | 3057 ± 510 | 2919 ± 545 | 2664 ± 570 | 2793 ± 628 | 2632 ± 527* | 2345 ± 433*† | |
| EVLWI (mL/kg) | HES | 11.22 ± 5.7† | 10.88 ± 7.0* | 11.66 ± 6.6* | 12.00 ± 6.1* | 12.22 ± 7.1 | 12.66 ± 7.0† |
| RF | 9.61 ± 2.1 | 9.07 ± 2.3 | 8.76 ± 1.2* | 8.76 ± 0.9 | 8.84 ± 1.0 | 9.46 ± 1.6 | |
| dPmax (mmHg/s) | HES | 703 ± 187.5† | 612 ± 118.2* | 717 ± 121.6† | 771 ± 125.3† | 791 ± 147.6† | 811 ± 144.9*† |
| RF | 588 ± 246.8 | 588 ± 286.3 | 642 ± 233.0† | 611 ± 278.3 | 639 ± 229.3 | 671 ± 223.8*† |
Data are presented as mean ± standard deviation. HES = colloid group, RF = crystalloid group
* p < 0.05 significantly different from T bsl
† p < 0.05 significantly different from T 0
# p < 0.05 significantly different between groups
Blood gas parameters during hemorrhage and fluid resuscitation
| Group |
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|
| pH | HES | 7.613 ± 0.038# | 7.603 ± 0.061# | 7.568 ± 0.068# | 7.54 ± 0.052 | 7.513 ± 0.043*† | 7.519 ± 0.042*† |
| RF | 7.541 ± 0.049 | 7.498 ± 0.063 | 7.448 ± 0.055*† | 7.393 ± 0.161* | 7.464 ± 0.055* | 7.48 ± 0.061* | |
| PaCO2 (mmHg) | HES | 28.1 ± 3.2 | 24.3 ± 3.8# | 26.1 ± 4.6# | 28.4 ± 4.4#† | 29.9 ± 3.1#† | 30.8 ± 4.5† |
| RF | 33.8 ± 5.3 | 33.9 ± 7.4 | 39.1 ± 6.8† | 38.6 ± 6.8† | 39.4 ± 6.6† | 38.3 ± 6.0† | |
| PaO2 (mmHg) | HES | 87.5 ± 12.2† | 102.8 ± 11.0* | 100.4 ± 9.6* | 95.8 ± 8.7 | 90.3 ± 13.0† | 84.5 ± 14.6† |
| RF | 99.0 ± 24.7 | 102.0 ± 25.7 | 96.7 ± 27.8† | 99.2 ± 29.3 | 94.9 ± 27.5 | 99.6 ± 30.9 | |
| HCO− 3 (mmol/l) | HES | 27.6 ± 2.3† | 24.4 ± 1.8* | 23.0 ± 1.5#* | 23.1 ± 2.0* | 23.5 ± 1.2#* | 24.4 ± 1.7#* |
| RF | 28.1 ± 1.4 | 25.5 ± 4.0 | 26.3 ± 3.3 | 26.6 ± 3.6 | 27.5 ± 2.7† | 27.7 ± 2.5† | |
| SaO2 (%) | HES | 97.8 ± 0.4 | 98.4 ± 0.3 | 98.2 ± 0.3 | 98 ± 0.4 | 97.7 ± 0.5 | 97.7 ± 0.4 |
| RF | 97.8 ± 1.2 | 97.8 ± 1.1 | 96.5 ± 2.7† | 96.9 ± 2.4 | 96.8 ± 2.2† | 96.8 ± 2.6 | |
| Lactate (mmol/L) | HES | 3.8 ± 2.0† | 6.9 ± 3.7* | 8.1 ± 3.0#*† | 7.6 ± 2.2#* | 7.1 ± 2.0#* | 5.5 ± 1.9#*† |
| RF | 2.1 ± 0.8† | 4.3 ± 2.0* | 4.7 ± 2.0* | 4.2 ± 1.8* | 3.8 ± 1.7* | 3.3 ± 1.4* | |
| Hct (%) | HES | 30.0 ± 4.8 | 26.7 ± 5.3 | 23.8 ± 5.2*† | 22.5 ± 4.5*† | 20.6 ± 3.5*† | 19.3 ± 3.9*† |
| RF | 34.5 ± 4.6† | 30.5 ± 5.6* | 27.1 ± 4.5*† | 25.1 ± 3.9*† | 23 ± 2.6*† | 22.4 ± 3.1*† | |
| Hb (g/dL) | HES | 9.8 ± 1.2 | 8.9 ± 1.4 | 8.1 ± 1.5*† | 7.7 ± 1.3*† | 7.1 ± 0.9*† | 6.7 ± 1.0*† |
| RF | 10.9 ± 1.2 | 9.9 ± 1.6 | 9 ± 1.3*† | 8.4 ± 1.1*† | 7.7 ± 0.9*† | 7.7 ± 1.0*† | |
| Ca++ (mmol/L) | HES | 0,87 ± 0,18 | 0,84 ± 0,23 | 0,84 ± 0,17 | 0,82 ± 0,24 | 0,84 ± 0,23 | 0,87 ± 0,29 |
| RF | 0,93 ± 0,3 | 0,87 ± 0,2 | 0,94 ± 0,23 | 0,86 ± 0,25 | 0,91 ± 0,31 | 0,89 ± 0,27 | |
| K+ (mmol/L) | HES | 2,48 ± 0,32 | 2,96 ± 0,49 | 3,04 ± 0,38* | 2,98 ± 0,29* | 2,9 ± 0,44 | 2,8 ± 0,48 |
| RF | 2,84 ± 0,44 | 3,11 ± 0,33 | 3,33 ± 0,34*† | 3,24 ± 0,27 | 3,22 ± 0,32 | 3,2 ± 0,27 | |
| Na+ (mmol/L) | HES | 139,9 ± 1,2 | 139,5 ± 1,2 | 140,7 ± 0,7† | 141,1 ± 1*† | 141,1 ± 0,9† | 141,2 ± 0,8† |
| RF | 138,9 ± 3,2 | 138,8 ± 3,2 | 139,7 ± 3,1† | 139,8 ± 2,8† | 139 ± 4,3 | 140,3 ± 2,9*† | |
| Cl− (mmol/L) | HES | 98 ± 1,9 | 98,7 ± 2,2 | 99,9 ± 1,7*† | 100,4 ± 1,3*† | 101,1 ± 1,8*† | 101,7 ± 1,5*† |
| RF | 97,1 ± 2,4 | 98,1 ± 2,7 | 99,6 ± 2,7*† | 100,4 ± 2,3*† | 100,4 ± 2,4*† | 102 ± 2,9*† | |
| Glucose (mmol/L) | HES | 8,1 ± 2,2 | 9,3 ± 3,5 | 6,8 ± 2,3† | 6 ± 1,8† | 6,4 ± 1† | 6,8 ± 0,8† |
| RF | 9 ± 2,9 | 10,9 ± 3,3 | 7,6 ± 3,3† | 6,4 ± 2,9*† | 6,2 ± 1,9*† | 6,1 ± 1,4* | |
| cv pH | HES | 7.578 ± 0.039# | 7.537 ± 0.07# | 7.516 ± 0.069# | 7.49 ± 0.047#*† | 7.476 ± 0.035*† | 7.495 ± 0.034* |
| RF | 7.503 ± 0.049† | 7.416 ± 0.049* | 7.39 ± 0.047*† | 7.41 ± 0.05* | 7.427 ± 0.055* | 7.442 ± 0.051* | |
| PcvCO2 (mmHg) | HES | 31.4 ± 2.7# | 30.3 ± 4.7# | 30.8 ± 5.3# | 31.7 ± 3.6# | 33.2 ± 3.7# | 33 ± 3.7# |
| RF | 39.4 ± 7.6 | 43.2 ± 7.6 | 47.6 ± 6.9*† | 46.1 ± 7.1 | 44.3 ± 7.5 | 42.1 ± 6.6 | |
| PcvO2 (mmHg) | HES | 46.7 ± 8.1† | 36.0 ± 9.9* | 40.7 ± 7.8*† | 44.5 ± 7.8† | 46.8 ± 5.2† | 45.4 ± 8.7† |
| RF | 48.3 ± 7.2† | 34.9 ± 4.0* | 39.3 ± 4.1*† | 44.8 ± 3.3† | 46.2 ± 5.2† | 48.6 ± 6.7† | |
| ScvO2 (%) | HES | 83.9 ± 7.3† | 69.1 ± 14.2* | 76.0 ± 9.9* | 79.7 ± 5.9*† | 82.6 ± 4.2† | 82.8 ± 4.8† |
| RF | 83.5 ± 8.1† | 59.9 ± 6.6* | 65.7 ± 7.9* | 72.7 ± 7.4*† | 76.2 ± 6.4*† | 79.0 ± 8.1*† | |
| Oxygen delivery index (mL/min/m2) | HES | 431.7 ± 83.9† | 203.5 ± 48.3* | 271.8 ± 55.7*† | 295.1 ± 59.8*† | 322.4 ± 60.7*† | 348.1 ± 57.7*† |
| RF | 460.3 ± 43.0 | 251.9 ± 83.5* | 269.2 ± 70.6* | 282.0 ± 54.6* | 296.4 ± 44.8*† | 354.6 ± 61.6*† | |
| Oxygen consumption | HES | 58.6 ± 26.8 | 58.7 ± 27.6 | 62.3 ± 34.7 | 55.0 ± 21.8 | 49.7 ± 16.2 | 52.9 ± 20.5 |
| RF | 65.2 ± 32.9† | 97.5 ± 36.9* | 85.3 ± 22.5* | 69.4 ± 16.5† | 63.4 ± 23.5† | 65.5 ± 31.0† | |
| Oxygen extraction (%) | HES | 14.2 ± 7.2† | 29.8 ± 14.2* | 22.6 ± 9.9* | 18.6 ± 6.0† | 15.5 ± 4.5† | 15.2 ± 5.1† |
| RF | 14.5 ± 8.2† | 38.8 ± 6.8* | 32.0 ± 7.1* | 25.0 ± 6.2*† | 21.3 ± 6.5*† | 18.4 ± 8.3*† | |
| Venous to arterial carbon dioxide gap (mmHg) | HES | 3.3 ± 1.4† | 6.0 ± 2.8#* | 4.7 ± 2.0# | 3.3 ± 1.9#† | 3.3 ± 1.2† | 2.2 ± 1.2† |
| RF | 5.6 ± 3.4† | 9.3 ± 1.6* | 8.5 ± 1.7*† | 7.5 ± 2.6 | 4.9 ± 2.0† | 3.8 ± 2.2*† |
Data are presented as mean ± standard deviation. HES = colloid group, RF = crystalloid group
*p < 0.05 significantly different from T bsl
† p < 0.05 significantly different from T 0
# p < 0.05 significantly different between groups
Fig. 2Resuscitation fluid (milliliters). Data are presented as median [IQR]. p = 0.002
Fig. 3Volume-replacement ratio: resuscitation fluid/total blood loss. Data are presented as median [IQR]. p = 0.002
Fig. 4Endothelial function. Plasma concentrations of syndecan-1 (a), glypican (b), syndecan-1 hematocrit ratio (c) and the glypican hematocrit ratio (d) are delineated. Data are presented as mean ± standard deviation. HES = colloid group, RF = crystalloid group. *p < 0.05 significantly different from T bsl. † p < 0.05 significantly different from T 0. # p < 0.05 significantly different between groups
Large controlled, randomized human trials. This table summarizes large controlled, randomized human trials in terms of population, type of fluid, ratio of crystalloid (Cr)/colloid (Co) solutions, end points, outcomes, and conclusions
| Trial | Population | Type of fluids | Ratio of Cr/Co | End points | Outcomes | Conclusions |
|---|---|---|---|---|---|---|
| Finfer 2004 SAFE ( | ICU patients hypovolemic instabilities | Albumin; saline | 1.32 | The clinicians decided the amount and rate of fluid. | 28-day mortality, RRT, new organ failure | No significant difference in 28-day mortality rate or development of new organ failure. |
| Brunkhorst 2008 VISEP ( | Sever septic ICU patients | HES; Ringer’s lactate | 1.32 | CVP 8 mmHg | 28-day mortality, RRT, new organ failure | HES was harmful, and its toxicity increased with accumulating doses. |
| Myburgh 2012 CHEST ( | ICU patients | HES 130/0.4; Saline | 1.20 | Safety authority *6% HES (130/0.4) was administered to a maximum dose of 50 mL/kg/day | 90-day mortality, AKI, ICU, and hospital stay, | No significant difference in 90-day mortality rate; however, the HES group received more RRT. |
| Guidet 2012 CRYSTMAS ( | Hemodynamic stabilization in patients with severe sepsis | HES 130/0.4; Saline | 1.23 | MAP ≥ 65 mmHg and at least two of | Required study fluid volume; ICU and hospital stay; SOFA score; AKI | Significantly less volume was required to achieve hemodynamic stabilization for HES vs. saline. |
| Perner 2012 6S ( | ICU patients with severe sepsis | HES 130/0.42; Ringer’s acetate | 1.00 | Resuscitation fluid used when ICU clinicians judged that volume expansion was needed (fluid challenge technique) | 90-day mortality, RRT | Increased 90-day mortality with HES; increased use of RRT with HES. |
| Annane 2013 CRISTAL ( | ICU patients with hypovolemic shock | Colloids (gelatins, dextrans, HES, 4% or 20% albumin); | 1.5 | The amount of fluid and duration of treatment was left at the investigators with restrictions: | 28- and 90-day mortality; days alive without the need for RRT, MV, or vasopressors | No difference in 28-day mortality; 90-day mortality lower in colloid group. |
| Yates 2013 ( | Medium- to high-risk elective colorectal surgery patients | HES 130/0.4; Hartman’s solutions | 1.69 | Before induction of anesthesia: 250 mL bolus of fluid was administered and the SV response recorded. If the SV increased by more than 10%, the bolus was repeated. | Day 5 post-op GI morbidity; post-op complications, LOS, coagulation and inflammation | No difference in any of the measured outcomes |
| Caironi 2014 ALBIOS ( | ICU patients with severe sepsis or septic shock | 20% albumin with crystalloid; crystalloid | 1.02 | Albumin group: 300 mL of 20% albumin solution. From day 1 until day 28 or ICU discharge. 20% albumin was administered on a daily basis, to maintain a serum albumin level of 30 g per liter or more. | 28- and 90-day mortality; organ dysfunction, LOS | No difference in mortality or other outcomes |
| Lobo 2010 ( | Healthy male subjects | Gelofusine (4% succinylated gelatine) Voluven (6% HES); saline | 1.00 | Compare the blood volume- expanding capacity | Changes in body water, blood volume and extra vascular fluid volume | Colloid solutions four times greater increase in blood volume as compared to saline, and extravasation was significantly higher after saline infusion. |